Literature DB >> 2989471

Human parvovirus (B19) and erythema infectiosum.

T Nunoue, K Okochi, P P Mortimer, B J Cohen.   

Abstract

An outbreak of erythema infectiosum ("fifth disease") was studied in Fukuoka, Japan, in 1980-1981. Human parvovirus (HPV) antigen was not detected in any patients, but anti-HPV, measured by countercurrent immunoelectrophoresis, was found in 33 of 34 affected children and in 21 (15%) of 141 children of the same ages without the disease. Immunoglobulin M class anti-HPV was present in all 25 children with erythema infectiosum tested. In a survey of hospital patients, the prevalence of anti-HPV detected by CIE was 12% in the cohort 5 to 9 years of age, 19% in the cohort 10 to 14 years, and 32 to 55% in the cohorts greater than or equal to 30 years. The antibody reactions in the cases of erythema infectiosum, which were already well established at the onset of disease, indicate that HPV was the cause of the outbreak.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2989471     DOI: 10.1016/s0022-3476(85)80610-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  11 in total

Review 1.  Erythema infectiosum and pregnancy-related complications.

Authors:  M Levy; S E Read
Journal:  CMAJ       Date:  1990-11-01       Impact factor: 8.262

2.  Erythema infectiosum (fifth disease) occurrence in Iowa.

Authors:  S J Naides
Journal:  Am J Public Health       Date:  1988-09       Impact factor: 9.308

Review 3.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

4.  Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue.

Authors:  Päivi Norja; Kati Hokynar; Leena-Maija Aaltonen; Renwei Chen; Annamari Ranki; Esa K Partio; Olli Kiviluoto; Irja Davidkin; Tomi Leivo; Anna Maria Eis-Hübinger; Beate Schneider; Hans-Peter Fischer; René Tolba; Olli Vapalahti; Antti Vaheri; Maria Söderlund-Venermo; Klaus Hedman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

5.  Low prevalence of antibody to human parvovirus B19 in Singapore.

Authors:  Y Matsunaga; K T Goh; E Utagawa; N Muroi
Journal:  Epidemiol Infect       Date:  1994-12       Impact factor: 2.451

6.  Persistence of parvovirus B19-DNA in blood of a child with severe combined immunodeficiency associated with chronic pure red cell aplasia.

Authors:  M Gahr; A Pekrun; H Eiffert
Journal:  Eur J Pediatr       Date:  1991-05       Impact factor: 3.183

7.  Parvovirus B19 infection in HIV-1 infected patients with anemia.

Authors:  K Gyllensten; A Sönnerborg; C Jorup-Rönström; M Halvarsson; Z Yun
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

8.  Prevalence of antihuman parvovirus B19 IgG antibodies in patients with refractory rheumatoid arthritis and polyarticular juvenile rheumatoid arthritis.

Authors:  A Mimori; Y Misaki; T Hachiya; K Ito; S Kano
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

9.  Pattern of parvovirus B 19 infection during different trimesters of pregnancy in Kuwait.

Authors:  M Makhseed; A Pacsa; M A Ahmed; S S Essa
Journal:  Infect Dis Obstet Gynecol       Date:  1999

10.  Global co-existence of two evolutionary lineages of parvovirus B19 1a, different in genome-wide synonymous positions.

Authors:  Marijke W A Molenaar-de Backer; Vladimir V Lukashov; Rob S van Binnendijk; Hein J Boot; Hans L Zaaijer
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.